Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study to assess safety, tolerability, pharmacokinetics of AMG 594 in healthy volunteers

Next Previous
Trial Profile

Phase 1 study to assess safety, tolerability, pharmacokinetics of AMG 594 in healthy volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2018

At a glance

  • Drugs AMG 594 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions

    • Most Recent Events

    • 01 Nov 2018 According to a Cytokinetics media release, the company expects to initiate this trial before the end of the year 2018.
    • 25 Oct 2018 New trial record
    • 16 Oct 2018 According to a Cytokinetics media release, IND has been filed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top